UnitedHealthcare is moving more drugs to the lower-cost tiers in its Medicare Advantage plans. Other plans will have $0 copays and insulin at a $25 copay.
UnitedHealthcare is offering expanded access and lower prescription drug costs for some 2023 Medicare Advantage and prescription drug plans. The insurer that 99% of members in standard and Chronic Special Needs Plans (C-SNPs) will have stable or reduced premiums – including nearly 3.3 million members with a $0 premium – and all will have stable or improved core and prescription drug benefits.
Additionally, all Medicare Advantage members will see stable ancillary benefits, with 91% receiving better-than-ever ancillary benefits like dental, hearing, over-the-counter and prescription drug coverage. The Medicare Advantage formulary will have more drugs in tier 1 and move even more commonly used drugs to lower tiers, which target conditions such as cardiovascular disease, depression, osteoarthritis, glaucoma, and overactive bladder. (See table below for a list tier changes.)
More plans will lower tier 1 retail copays to $0, giving nearly all members in standard plans and Chronic Special Needs Plans (C-SNPs) free access to the most common adherence medications. And 100% of members will have $0 tier 1 and 2 copays through Optum Home Delivery, up from 93% in 2022. Additionally, 87% of members will have no Rx deductibles, up from 59% in 2022.
All members without Extra Help enrolled in C-SNPs will have access to insulin at $25 ($10 less than standard plans) in addition to diabetic supplies on tier 2, giving access to $0 copays for supplies when using home delivery. C-SNP members will also have access to eight medications on a lower drug tier that target cardiovascular disease.
UnitedHealthcare will continue to expand access to $0 copays on covered drugs to 96% of its members enrolled in Dual Special Needs Plan (D-SNP).
Annual enrollment for Medicare begins Oct. 15, 2022, and continues through Dec. 7, 2022.
* updated to include table with tier changes
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More